ETERNA THERAPEUTICS IN

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

02 May 2023 06:30:18 By Nasdaq GlobeNewswire

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

11 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board

28 Mar 2023 07:30:33 By Nasdaq GlobeNewswire

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

20 Mar 2023 15:10:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

22 Feb 2023 07:00:47 By Nasdaq GlobeNewswire

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

04 Jan 2023 07:30:03 By Nasdaq GlobeNewswire

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

01 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

18 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

17 Oct 2022 07:30:00 By Nasdaq GlobeNewswire